PL3773689T3 - Peptydy antygenowe do zapobiegania i leczenia raka - Google Patents

Peptydy antygenowe do zapobiegania i leczenia raka

Info

Publication number
PL3773689T3
PL3773689T3 PL19716176.3T PL19716176T PL3773689T3 PL 3773689 T3 PL3773689 T3 PL 3773689T3 PL 19716176 T PL19716176 T PL 19716176T PL 3773689 T3 PL3773689 T3 PL 3773689T3
Authority
PL
Poland
Prior art keywords
cancer
prevention
treatment
antigenic peptides
antigenic
Prior art date
Application number
PL19716176.3T
Other languages
English (en)
Inventor
Laurent Chene
Christophe Bonny
Francesco STROZZI
Original Assignee
Enterome S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterome S.A. filed Critical Enterome S.A.
Publication of PL3773689T3 publication Critical patent/PL3773689T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001119—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL19716176.3T 2018-04-11 2019-04-11 Peptydy antygenowe do zapobiegania i leczenia raka PL3773689T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305444 2018-04-11
EP2018077512 2018-10-09
PCT/EP2019/059329 WO2019197567A2 (en) 2018-04-11 2019-04-11 Antigenic peptides for prevention and treatment of cancer

Publications (1)

Publication Number Publication Date
PL3773689T3 true PL3773689T3 (pl) 2023-03-13

Family

ID=66092357

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19716176.3T PL3773689T3 (pl) 2018-04-11 2019-04-11 Peptydy antygenowe do zapobiegania i leczenia raka

Country Status (18)

Country Link
US (2) US12016910B2 (pl)
EP (2) EP4169528A1 (pl)
JP (2) JP7384819B2 (pl)
CN (1) CN112118863A (pl)
AU (1) AU2019253217A1 (pl)
BR (1) BR112020020780A2 (pl)
CA (1) CA3094262A1 (pl)
DK (1) DK3773689T5 (pl)
ES (1) ES2935702T3 (pl)
FI (1) FI3773689T3 (pl)
HR (1) HRP20230007T1 (pl)
HU (1) HUE060791T2 (pl)
LT (1) LT3773689T (pl)
MX (2) MX2020010701A (pl)
PL (1) PL3773689T3 (pl)
RS (1) RS63873B1 (pl)
SI (1) SI3773689T1 (pl)
WO (1) WO2019197567A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110022894B (zh) 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
CA3039322A1 (en) 2016-10-07 2018-04-12 Enterome S.A. Immunogenic compounds for cancer therapy
FI4021487T3 (fi) 2019-11-15 2024-02-06 Enterome S A Antigeenisiä peptidejä b-solun pahanlaatuisuuden ehkäisyyn ja hoitoon
CN111197040B (zh) * 2020-01-21 2023-08-08 福建亿彤生物科技有限公司 壳多糖酶3样蛋白1（chi3l1）抗原表位肽、抗原、抗体、用途及试剂盒
WO2023187127A1 (en) * 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
IT202200006785A1 (it) * 2022-04-06 2023-10-06 Istituto Naz Tumori Irccs Fondazione G Pascale Analoghi di antigeni tumorali da microbiota e usi relativi
KR20240017325A (ko) * 2022-07-29 2024-02-07 주식회사 엘지화학 항원 전달용 재조합 융합 단백질 및 이의 이용

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
WO2000056360A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against antigens from bacteriae
CA2370413A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
FR2798128B1 (fr) 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
BR0017136A (pt) 2000-02-23 2003-02-25 Epimmune Inc Peptìdeos de ligação ao hla e seus usos.
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
EP1496923A4 (en) 2002-03-22 2005-10-19 Penn State Res Found IMMUNOTHERAPY AGAINST CANCER
CA2500715A1 (en) 2002-10-03 2004-04-15 Epimmune, Inc. Hla binding peptides and their uses
WO2005076001A2 (en) 2004-02-06 2005-08-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
EP2089057A2 (en) 2006-12-11 2009-08-19 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
JP5555952B2 (ja) 2007-08-20 2014-07-23 オンコセラピー・サイエンス株式会社 Ｆｏｘｍ１ペプチドおよびこれを含む薬剤
HUE024541T2 (hu) 2008-05-14 2016-01-28 Immatics Biotechnologies Gmbh Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek
EP2324057B1 (en) 2008-08-12 2018-03-21 MSD Italia S.r.l. Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers
EP2172211B1 (en) * 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
WO2010129033A2 (en) 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
EP2500350B1 (en) 2009-11-03 2018-08-15 Korea University Research And Business Foundation Composite of a protein comprising zinc oxide-bonding peptides and zinc oxide nanoparticles, and use thereof
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
US9314516B2 (en) 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
ES2722799T3 (es) 2010-08-24 2019-08-16 Univ Pittsburgh Commonwealth Sys Higher Education Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2797634A4 (en) 2011-12-29 2015-08-05 Moderna Therapeutics Inc MODIFIED mRNA ENCODING POLYPEPTIDES PENETRATING IN CELLS
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
EP2828664B1 (en) 2012-03-19 2018-09-26 Stemline Therapeutics Inc. Methods for treating and monitoring the status of cancer
US9428813B2 (en) 2012-03-26 2016-08-30 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
EP4321218A3 (en) 2012-05-16 2024-04-24 Stemline Therapeutics, Inc. Cancer stem cell targeted cancer vaccines
US20140141044A1 (en) 2012-11-12 2014-05-22 Dana-Farber Cancer Institute, Inc. Cord Colitis Syndrome Pathogen
EP2929045B1 (en) 2012-12-05 2020-12-02 SOLA Biosciences LLC Protein expression enhancing polypeptides
US9764037B2 (en) 2012-12-06 2017-09-19 Victoria Link Limited Conjugate compounds
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
SG11201610177UA (en) 2014-06-06 2017-01-27 Herlev Hospital Determining antigen recognition through barcoding of mhc multimers
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
SG11201706418QA (en) 2015-03-31 2017-10-30 Agency Science Tech & Res Method for antigen loading of dendritic cells and vaccine
EP3464630A1 (en) 2016-05-23 2019-04-10 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Methods of diagnosing cancer using cancer testis antigens
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
CA3039322A1 (en) 2016-10-07 2018-04-12 Enterome S.A. Immunogenic compounds for cancer therapy
CN110022894B (zh) 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
AU2018348432A1 (en) * 2017-10-09 2020-04-02 Enterome S.A. Microbiota sequence variants of tumor-related antigenic epitopes
US20210106652A1 (en) 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
BR112022007203A2 (pt) 2019-10-16 2022-07-05 Enterome S A Compostos imunogênicos para tratamento de câncer adrenal
FI4021487T3 (fi) 2019-11-15 2024-02-06 Enterome S A Antigeenisiä peptidejä b-solun pahanlaatuisuuden ehkäisyyn ja hoitoon

Also Published As

Publication number Publication date
WO2019197567A3 (en) 2019-11-28
MX2020010701A (es) 2021-01-20
JP2024016203A (ja) 2024-02-06
EP4169528A1 (en) 2023-04-26
US12016910B2 (en) 2024-06-25
HUE060791T2 (hu) 2023-04-28
CA3094262A1 (en) 2019-10-17
LT3773689T (lt) 2023-01-25
US20240293520A1 (en) 2024-09-05
JP7384819B2 (ja) 2023-11-21
ES2935702T3 (es) 2023-03-09
US20210113678A1 (en) 2021-04-22
DK3773689T5 (da) 2024-08-19
MX2023014457A (es) 2023-12-15
JP2021520818A (ja) 2021-08-26
DK3773689T3 (da) 2023-01-16
FI3773689T3 (fi) 2023-01-31
EP3773689A2 (en) 2021-02-17
HRP20230007T1 (hr) 2023-03-03
CN112118863A (zh) 2020-12-22
AU2019253217A1 (en) 2020-10-15
BR112020020780A2 (pt) 2021-03-02
RS63873B1 (sr) 2023-02-28
SI3773689T1 (sl) 2023-02-28
WO2019197567A2 (en) 2019-10-17
EP3773689B1 (en) 2022-11-09

Similar Documents

Publication Publication Date Title
FI3773689T3 (fi) Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
HK1252873A1 (zh) 用於癌症治療和預防的疫苗
IL276808A (en) Preparations and methods for the treatment of cancer
SG11202104923YA (en) Pharmaceutical combination for treatment of cancer
IL279347A (en) Gremlin-1 antagonist for cancer prevention and treatment
IL268814A (en) Preparations and methods for the treatment of cancer
SI4021487T1 (sl) Antigenski peptidi za preprečevanje in zdravljenje b-celične malignosti
IL286297A (en) Minimal residual cancer treatment methods
SG11202011117VA (en) Treatment of cancer
SG11202006160RA (en) Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer
GB201812647D0 (en) Viral vectors and methods for the prevention or treatment of cancer
IL272147A (en) Methods and preparations for the treatment of cancer
PL3630112T3 (pl) Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu
IL280262A (en) Compositions and methods for treating cancer
GB201810635D0 (en) Peptides and cancer treatment
IL277313B (en) Pharmaceutical preparations of sposin c and methods for the treatment of cancer
GB201820975D0 (en) Methods of cancer treatment
PT4021487T (pt) Péptidos antigénicos para prevenir e tratar neoplasia maligna de células b
GB201815694D0 (en) Prevention and treatment of cancer
GB201809946D0 (en) Prevention and treatment of cancer
IL281091A (en) Peptide therapy for cancer treatment and their uses
IL262945A (en) Medicament for treatment and/or prophylactic treatment of breast cancer
IL277112A (en) Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer
GB201820098D0 (en) Methods of cancer treatment
GB201812127D0 (en) Cancer treatment using immunoconjugates and immune check-point inhibitors